Study drug
An LFHC formulation (orally-administered bendamustine) containing 10 or 30 mg of bendamustine (as a free base) in one capsule was administered once daily in the fasted state (fasting for 2 h before administration and 1 h after administration). The individual nominal dose at each level was calculated using the body surface area (BSA), and the nearest available dose was selected using 30 mg capsules in Cohort 1 and using a combination of 10 and 30 mg capsules in Cohorts 2 and 3.